NeuroPace Revenue Jumps 19.6% in Q2, Net Loss Narrows Slightly

TL;DR

**NeuroPace is burning cash despite revenue growth; watch for sustained profitability before jumping in.**

AI Summary

NeuroPace Inc. reported a significant increase in revenue for the three months ended June 30, 2025, reaching $16.5 million, up from $13.8 million in the prior-year period, representing a 19.6% increase. For the six months ended June 30, 2025, total revenue was $32.1 million, a 17.5% increase from $27.3 million in the same period of 2024. Despite revenue growth, the company continues to operate at a net loss. The net loss for the three months ended June 30, 2025, was $17.2 million, a slight improvement from a net loss of $18.1 million in the comparable 2024 period. The net loss for the six months ended June 30, 2025, was $35.0 million, compared to $36.2 million in the first half of 2024. Key business changes include continued investment in research and development, with expenses at $10.1 million for the quarter, and selling, general, and administrative expenses at $20.2 million. The company's strategic outlook focuses on expanding the market for its RNS System, a brain-responsive neurostimulation system for epilepsy. Risks include ongoing operating losses and the need for additional capital, as evidenced by the follow-on offering and at-the-market equity offering in Q1 2025, which increased additional paid-in capital by $10.0 million and $1.0 million respectively.

Why It Matters

NeuroPace's continued revenue growth, up 19.6% in Q2 2025, signals increasing adoption of its RNS System, which is crucial for a medical device company in a competitive market. However, persistent net losses, despite narrowing slightly to $17.2 million, highlight ongoing challenges in achieving profitability and could impact investor confidence. For employees, sustained growth in product adoption offers job security and potential for expansion, while customers benefit from continued innovation in epilepsy treatment. The broader market watches NeuroPace as a bellwether for innovation in neurostimulation, competing with established players and emerging technologies in the neurological device space.

Risk Assessment

Risk Level: high — NeuroPace reported a net loss of $17.2 million for Q2 2025 and $35.0 million for the first six months of 2025, indicating continued unprofitability. The company's reliance on equity offerings, such as the follow-on offering and at-the-market equity offering in Q1 2025, to raise capital (totaling $11.0 million) suggests ongoing liquidity needs and potential for future dilution.

Analyst Insight

Investors should monitor NeuroPace's next few quarters for a clear path to profitability and reduced reliance on equity financing. While revenue growth is positive, the persistent net losses and capital raises indicate significant financial risk, warranting a cautious approach.

Financial Highlights

debt To Equity

N/A

revenue

$16.5M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$17.2M

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

+19.6%

Revenue Breakdown

Key Numbers

• $16.5M — Q2 2025 Revenue (19.6% increase from Q2 2024's $13.8M)
• $32.1M — H1 2025 Revenue (17.5% increase from H1 2024's $27.3M)
• -$17.2M — Q2 2025 Net Loss (Narrows from -$18.1M in Q2 2024)
• -$35.0M — H1 2025 Net Loss (Narrows from -$36.2M in H1 2024)
• $10.1M — Q2 2025 R&D Expenses (Continued investment in product development)
• $20.2M — Q2 2025 SG&A Expenses (Significant operational cost)
• $11.0M — Q1 2025 Capital Raised (From equity offerings, indicating need for funding)

Key Players & Entities

• NeuroPace Inc. (company) — filer of the 10-Q
• RNS System (product) — brain-responsive neurostimulation system for epilepsy
• $16.5 million (dollar_amount) — total revenue for Q2 2025
• $13.8 million (dollar_amount) — total revenue for Q2 2024
• $17.2 million (dollar_amount) — net loss for Q2 2025
• $18.1 million (dollar_amount) — net loss for Q2 2024
• $32.1 million (dollar_amount) — total revenue for the six months ended June 30, 2025
• $35.0 million (dollar_amount) — net loss for the six months ended June 30, 2025
• $10.0 million (dollar_amount) — additional paid-in capital from follow-on offering in Q1 2025
• $1.0 million (dollar_amount) — additional paid-in capital from at-the-market equity offering in Q1 2025

FAQ

Risk Factors

• Ongoing Operating Losses [high — financial]: The company reported a net loss of $17.2 million for Q2 2025 and $35.0 million for H1 2025. These losses, while slightly narrowed from the prior year, highlight the continued need for capital to fund operations.
• Need for Additional Capital [high — financial]: NeuroPace raised $11.0 million in Q1 2025 through a follow-on offering ($10.0 million) and an at-the-market equity offering ($1.0 million). This demonstrates reliance on external financing to cover operational deficits and fund growth initiatives.
• High SG&A Expenses [medium — operational]: Selling, General, and Administrative (SG&A) expenses were $20.2 million for Q2 2025. While necessary for market expansion, these costs represent a significant portion of the company's expenditures and contribute to the net loss.
• Research and Development Investment [medium — operational]: R&D expenses were $10.1 million for Q2 2025. Continued investment is crucial for product development and market penetration of the RNS System, but it also adds to the company's overall expenses.
• Regulatory Compliance [medium — regulatory]: As a medical device company, NeuroPace is subject to stringent regulatory oversight from bodies like the FDA. Any changes in regulations or compliance issues could impact product approval, market access, and operational costs.

Industry Context

NeuroPace operates in the medical device sector, specifically focusing on neurostimulation for neurological disorders like epilepsy. The market is characterized by high R&D costs, long product development cycles, and significant regulatory hurdles. Competitors may include other neuromodulation companies and pharmaceutical treatments for epilepsy.

Regulatory Implications

As a medical device manufacturer, NeuroPace is subject to rigorous FDA regulations for product safety and efficacy. Compliance with these regulations is critical for market access and continued sales. Any adverse regulatory actions or changes in the regulatory landscape could significantly impact the company's operations and financial performance.

What Investors Should Do

1. Monitor SG&A and R&D spending
2. Assess cash burn rate and future funding needs
3. Track RNS System market penetration and adoption

Key Dates

• 2025-06-30: End of Q2 2025 — Reporting period for the 10-Q, showing revenue growth and continued net loss.
• 2025-08-12: 10-Q Filing Date — The date the company officially submitted its quarterly financial report to the SEC.
• 2025-01-01 to 2025-03-31: Q1 2025 Equity Offerings — Raised $11.0 million, indicating a need for capital to sustain operations and growth.

Glossary

RNS System

A brain-responsive neurostimulation system designed to treat epilepsy. (This is NeuroPace's core product, and its market expansion is central to the company's revenue growth strategy.)

Follow-on Offering

The sale of additional shares of stock by a public company after its initial public offering. (Indicates the company is seeking additional capital from investors, as seen with the $10.0 million raised in Q1 2025.)

At-the-market equity offering

A type of offering where a company sells shares of its stock on a stock exchange over a period of time at prevailing market prices. (Another method for raising capital, contributing $1.0 million in Q1 2025.)

SG&A Expenses

Selling, General, and Administrative expenses, which include costs related to marketing, sales, and corporate overhead. (A significant expense category for NeuroPace, impacting profitability.)

Year-Over-Year Comparison

NeuroPace Inc. demonstrated robust revenue growth in the second quarter of 2025, with a 19.6% increase to $16.5 million compared to the prior year. This growth continued into the first half of the year, with revenue up 17.5% to $32.1 million. Despite this top-line improvement, the company continues to operate at a net loss, though the loss has slightly narrowed year-over-year for both the quarter (-$17.2M vs. -$18.1M) and the half-year (-$35.0M vs. -$36.2M). No new significant risks were introduced, but the ongoing need for capital, evidenced by Q1 2025 equity raises totaling $11.0 million, remains a key concern.

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share NPCE The Nasdaq Sto

Filing Documents

• npce-20250630.htm (10-Q) — 1264KB
• exhibit101-rebeccakuhnsepa.htm (EX-10.1) — 70KB
• exhibit102-patrickwilliams.htm (EX-10.2) — 48KB
• exhibit103-midcapcreditagr.htm (EX-10.3) — 1295KB
• exhibit311certificationsq2.htm (EX-31.1) — 10KB
• exhibit312certificationsq2.htm (EX-31.2) — 10KB
• exhibit321certificationsq2.htm (EX-32.1) — 7KB
• 0001528287-25-000022.txt ( ) — 7961KB
• npce-20250630.xsd (EX-101.SCH) — 44KB
• npce-20250630_cal.xml (EX-101.CAL) — 64KB
• npce-20250630_def.xml (EX-101.DEF) — 234KB
• npce-20250630_lab.xml (EX-101.LAB) — 648KB
• npce-20250630_pre.xml (EX-101.PRE) — 422KB
• npce-20250630_htm.xml (XML) — 616KB

Financial Information

Part I. Financial Information Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Balance Sheets 1 Condensed Statements of Operations and Comprehensive Loss 2 Condensed Statements of Stockholders' Equity 3 Condensed Statements of Cash Flows 5 Notes to Unaudited Interim Condensed Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 34 Item 4.

Controls and Procedures

Controls and Procedures 35

Other Information

Part II. Other Information Item 1.

Legal Proceedings

Legal Proceedings 36 Item 1A.

Risk Factors

Risk Factors 37 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 92 Item 3. Defaults Upon Senior Securities 93 Item 4. Mine Safety Disclosures 94 Item 5. Other Information 94 Item 6. Exhibits 95

Signatures

Signatures SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements regarding results or events that may occur in the future contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial condition, as well as expectations of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would," or the negative of these words or other similar terms or expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties, factors and assumptions more thoroughly described in "Risk Factors." These risks are not exhaustive. Other sections of this Quarterly Report on Form 10-Q, as well as our other disclosures and filings, include additional factors that could harm our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in, or implied by, any forward-looking statements. You should not rely on these forward-looking statements as predictions of future events. We cannot assure yo

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Unaudited Financial Statements

Item 1. Unaudited Financial Statements NeuroPace, Inc. Condensed Balance Sheets (unaudited) June 30, December 31, (in thousands, except share and per share amounts) 2025 2024 Assets Current assets Cash and cash equivalents $ 22,857 $ 13,430 Short-term investments 39,284 39,325 Accounts receivable 13,554 12,851 Inventory 16,346 13,381 Prepaid expenses and other current assets 1,701 2,352 Total current assets 93,742 81,339 Property and equipment, net 1,156 1,052 Operating lease right-of-use asset 11,007 11,843 Restricted cash 122 122 Deferred offering costs — 276 Other assets 87 15 Total assets $ 106,114 $ 94,647 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 4,721 $ 2,954 Accrued liabilities 9,740 9,787 Operating lease liability 1,986 1,860 Deferred revenue 696 555 Total current liabilities 17,143 15,156 Long-term debt 58,616 59,525 Operating lease liability, net of current portion 10,917 11,953 Total liabilities 86,676 86,634 Commitments and contingencies (Note 5) Stockholders' equity Preferred stock, $ 0.001 par value, 10,000,000 shares authorized and no shares issued and outstanding as of June 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value, 200,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 33,044,371 and 30,145,039 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 33 30 Additional paid-in capital 565,595 538,933 Accumulated deficit ( 546,190 ) ( 530,950 ) Total stockholders' equity 19,438 8,013 Total liabilities and stockholders' equity $ 106,114 $ 94,647 The accompanying notes are an integral part of these unaudited interim condensed financial statements. 1 NeuroPace, Inc. Condensed Statements of Operations and Comprehensive Loss (unaudited) Three Months Ended June 30, Six Months Ended June 30, (in thousands, except share and per share amounts) 2025 2024 2025 2024 Revenue $ 23,520 $ 19,256 $ 46,044 $ 37,38

View Full Filing

View this 10-Q filing on SEC EDGAR